Abstract

HIV-1 group M was transmitted to humans nearly one century ago. The virus has since evolved to form distinct clades, which spread to different regions of the world. The envelope glycoproteins (Envs) of HIV-1 have rapidly diversified in all infected populations. We examined whether key antigenic sites of Env and signatures of vaccine efficacy are evolving toward similar or distinct structural forms in different populations worldwide. Patterns of amino acid variants that emerged at each position of Env were compared between diverse HIV-1 clades and isolates from different geographic regions. Interestingly, at each Env position, the amino acid in the clade ancestral or regional-founder virus was replaced by a unique frequency distribution (FD) of amino acids. FDs are highly conserved in populations from different regions worldwide and in paraphyletic and monophyletic subclade groups. Remarkably, founder effects of Env mutations at the clade and regional levels have gradually decreased during the pandemic by evolution of each site toward the unique combination of variants. Therefore, HIV-1 Env is evolving at a population level toward well-defined "target" states; these states are not specific amino acids but rather specific distributions of amino acid frequencies. Our findings reveal the powerful nature of the forces that guide evolution of Env and their conservation across different populations. Such forces have caused a gradual decrease in the interpopulation diversity of Env despite an increasing intrapopulation diversity.IMPORTANCE The Env protein of HIV-1 is the primary target in AIDS vaccine design. Frequent mutations in the virus increase the number of Env forms in each population, limiting the efficacy of AIDS vaccines. Comparison of newly emerging forms in different populations showed that each position of Env is evolving toward a specific combination of amino acids. Similar changes are occurring in different HIV-1 subtypes and geographic regions toward the same position-specific combinations of amino acids, often from distinct ancestral sequences. The predictable nature of HIV-1 Env evolution, as shown here, provides a new framework for designing vaccines that are tailored to the unique combination of variants expected to emerge in each virus subtype and geographic region.

Highlights

  • IMPORTANCE The envelope glycoproteins (Envs) protein of HIV-1 is the primary target in AIDS vaccine design

  • We focused on two components of Env that contain multiple broadly neutralizing antibodies (BNAbs) epitopes: (i) the glycan shield of gp120, composed of multiple N-linked glycosylation sites that adorn the surface of the molecule [18, 19]; and (ii) the second variable loop (V2) segment at the trimer apex, which contains two signatures of vaccine efficacy identified in sieve analysis of the RV144 trial results [20,21,22,23]

  • From the clade ancestral or regional-founder virus, each position of Env has evolved toward a unique combination of amino acids that is highly conserved in different populations worldwide

Read more

Summary

Introduction

IMPORTANCE The Env protein of HIV-1 is the primary target in AIDS vaccine design. Frequent mutations in the virus increase the number of Env forms in each population, limiting the efficacy of AIDS vaccines. The envelope glycoproteins (Envs) on the surface of the virus are the most diverse of all proteins encoded by HIV-1; more than 20% of Env amino acids can differ between viruses from the same clade [8,9,10,11] This protein continues to diversify at a population level [11,12,13,14]. From the clade ancestral or regional-founder virus, each position of Env has evolved toward a unique combination (frequency distribution [FD]) of amino acids that is highly conserved in different populations worldwide. For many Env positions targeted by BNAbs, founder effects of the virus at the clade and regional levels are gradually decreasing by evolution toward their site-specific FDs of amino acids

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call